LGM Pharma COVID-19 Business Update

Dear Valued Customers and Partners,
 
We recognize that with the constantly changing COVID-19 situation around the world, this is an unprecedented time for everyone – a time that, for many, is filled with uncertainty. LGM Pharma is closely monitoring this evolving situation and any potential impact on our business to ensure we can continue to deliver the high-quality products and services our customers rely on.
 
As the situation evolves, please continue to reach out to your point of contact at LGM Pharma to help answer any questions or concerns you might have. Our goal is to remain in constant contact with our clients and manufacturers to fully understand and address concerns regarding the impact to the global API supply chain. This will allow us to help mitigate risk early to ensure supply of critical APIs necessary for our client’s continued research efforts, clinical trials and commercial production of necessary therapeutics in this challenging time.
 
While it is impossible to predict all impacts of this global crisis, our senior leadership team remains vigilant and is monitoring the situation in real time and responding rapidly as conditions develop. Our commitment is to communicate any changes to our services as swiftly as possible.
 
For additional information about COVID-19, visit the Centers for Disease Control and Prevention at cdc.gov.
 
As always, we greatly appreciate your business and will continue to do all that we can to serve you.
 
Please be safe and stay healthy.
 
Sincerely,
Prasad Raje
CEO

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. We’re working to update our website to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service